Clinical trial Recruiting at 1 site Phase 1 Interventional Ages 2 to 12

Ketamine-Propofol vs Dexmedetomidine-Propofol Sedation for Pediatric Cardiac Catheterization

Official title: a Comparive Study of Ketamine-Propofol Versus Dexmedetomidine-Propofol Sedation in Pediatric Patients Undergoing Cardiac Catheterization for Device Closure of Simple Left-to-right Shunts

Run by Ain Shams University · NCT07669012 · Data updated 2026-11-12

This study tests two sedative combinations to see which is safer and more effective for children 2–12 undergoing device closure of simple left-to-right heart shunts.

More Sedation and Analgesia trials

Quick facts

PhasePhase 1
Study typeInterventional
Ages2 Years to 12 Years
SexAll
Enrollment124 (estimated)
SponsorAin Shams University
Academic / other
Locations1 site (Cairo)
StatusRecruiting
StartedOctober 22, 2025
Main results expectedOctober 22, 2026
Study endsFebruary 15, 2027
Registry record updatedJune 25, 2026
Trial IDNCT07669012 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children aged 2–12 years, ≥10 kg, ASA II-III, scheduled for elective transcatheter closure of a simple left-to-right shunt such as ASD, small VSD, or PDA, and whose guardians consent to participation.

Probably not a fit

Patients with cyanotic heart disease, complex congenital lesions, or those requiring general anesthesia with a cuffed endotracheal tube may not benefit from these specific sedation regimens.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional Phase 1 trial compares ketamine-propofol with dexmedetomidine-propofol sedation in children undergoing transcatheter device closure of simple left-to-right shunts. Eligible participants are 2–12 years old, weighing at least 10 kg, with ASA II-III status, and scheduled for elective closure of conditions such as ASD, small muscular VSD, or PDA. Procedures may be guided by transthoracic or transesophageal echocardiography per the cardiology team's practice. The study aims to assess safety and efficacy of the two sedation regimens during the catheterization procedure. Lead sponsor is Ain Shams University, with procedures conducted at Ain Shams University Hospital in Cairo, Egypt.

Why it matters

Potential benefit: If successful, the trial could identify a preferred sedation approach that improves safety and comfort for pediatric patients undergoing device closure procedures.

How similar studies have gone: Sedation with ketamine-propofol and dexmedetomidine-propofol has been explored in pediatric procedural settings, but direct head-to-head comparisons for this specific device-closure context are limited, making this approach relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 2-12 years, male or female
* Weight ≥ 10 kg
* Scheduled for elective transcatheter device closure of a simple left-to-right shunt, including:
* Secundum atrial septal defect (ASD) suitable for device closure
* Small muscular ventricular septal defect (VSD) eligible for percutaneous device closure
* Patent ductus arteriosus (PDA) closure
* Procedure performed with transthoracic or transesophageal echocardiographic guidance according to the cardiology team's practice
* ASA physical status II-III
* Written informed consent obtained from a parent or legal guardian

Exclusion Criteria:

* Cyanotic congenital heart disease
* Complex congenital cardiac lesions
* Risk of pulmonary hypertensive crisis
* Requirement for general anesthesia and cuffed endotracheal tube at the discretion of the cardiology or anesthesia team
* Baseline oxygen requirement \> 2 L/min
* Use of noninvasive ventilation
* Known allergy or intolerance to ketamine, dexmedetomidine, or propofol
* Significant hepatic impairment
* Significant renal impairment
* Advanced atrioventricular block
* Clinically significant bradyarrhythmia
* Uncontrolled epilepsy
* Raised intracranial pressure
* Severe obstructive sleep apnea
* Craniofacial anomalies associated with anticipated difficult airway management
* BMI \> 97th percentile when judged to confer high risk of sedation-related airway obstruction
* Current beta-blocker use
* Current clonidine use
* Acute upper respiratory tract infection within 2 weeks before the procedure
* Emergency or add-on procedures
* Anticipated procedure duration \< 20 minutes
* Anticipated procedure duration \> 3 hours

Where it's running

  • Ain shams university hospital
    Cairo, Egypt
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.